Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters Corporation (WAT) will hold its third-quarter 2026 financial results conference call on November 3, 2026, at 8:00 a.m. Eastern Time. A live webcast will be available on Waters' Investor Relations website. The replay will remain available until at least December 1, 2026, at midnight Eastern Time.
Waters (WAT) announced the global commercial launch of the BD FACSDiscover A7 Cell Analyzer on September 14, 2026.
The instrument uses BD SpectralFX™ Technology to support routine 50+ parameter spectral flow cytometry experiments and combines high spectral resolution and sensitivity with ease-of-use features. Together with FACSTruQ™ Technology, it delivers next-generation automated setup and quality control, achieving a coefficient of variation of less than 10% across a palette of more than 50 dyes. An integrated autoloader and BD FACSChorus™ Software provide guided workflows, and the system is now available to order worldwide through local representatives, with BD remaining the legal manufacturer during ongoing regulatory transfers.
Waters (WAT)/b) will participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference on September 23, 2026, at 12:00 PM BST / 7:00 AM Eastern Time. Waters President and CEO Udit Batra, Ph.D., will represent the company. A live webcast will be accessible via the section of Waters’ Investor Relations website, with a replay available for 90 days.
Waters (NYSE: WAT) announced that President and CEO Udit Batra, Ph.D., will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 10:15 AM Eastern Time. A live webcast and 90-day replay will be available via the Events & Presentations section of Waters’ investor relations website.
Waters (NYSE: WAT) reported Q2 2026 revenue of $1.645 billion, more than double the prior year and above guidance, including $828 million organic revenue (+7% reported, +9% constant currency) and $817 million from the acquired Biosciences and Diagnostic Solutions businesses (+4% versus prior-year comparable).
GAAP diluted EPS was a loss of $1.39, primarily reflecting acquisition-related purchase accounting charges, while adjusted EPS rose 3% to $3.05, landing at the high end of guidance. Divisional revenue reached $669 million for Analytical Sciences, $368 million for Biosciences, $521 million for Advanced Diagnostics, and $87 million for Materials Sciences.
According to Waters, strong execution and a broader end-market recovery led the company to raise all components of its full-year 2026 outlook, now targeting organic constant currency revenue growth of 7–9%, acquired business revenue of about $3.045 billion, total revenue of $6.415–$6.476 billion, and adjusted EPS of $14.45–$14.65, implying 10–12% year-over-year adjusted EPS growth.
Waters (NYSE: WAT) launched the Xevo TQ Absolute XR IVD Mass Spectrometer, a new component of its MassTrak LC-MS/MS IVD System portfolio, at the ADLM 2026 Annual Meeting. The IVD-compliant system targets routine clinical testing across women's health, hormone-related cancer assessment, and toxicology.
According to Waters, the Xevo TQ Absolute XR IVD System delivers up to 5x greater sensitivity than in-class instruments, enabling lower limits of detection from smaller sample volumes for complex biological matrices. The system features the new StepWave XR Ion Guide, which is reported to provide up to a six-fold increase in robustness versus the Xevo TQ Absolute IVD System by maintaining ion ratio consistency for longer when analyzing challenging clinical samples. The complete MassTrak LC-MS/MS IVD configuration pairs the Xevo TQ Absolute XR with the ACQUITY UPLC I-Class PLUS System to support fast, accurate analysis and a user-friendly design aimed at maximizing laboratory uptime. The system is available to order immediately.
Waters (NYSE: WAT) will hold its Q2 2026 financial results conference call on Tuesday, August 4, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay will be available on the company’s Investor Relations website until at least September 1, 2026.
Waters is a global life sciences and diagnostics company focused on analytical technologies, informatics, and services for regulated, high-volume testing environments, supporting medicine development, food and water safety, and disease detection.
Waters (NYSE:WAT) and IMU Biosciences announced a strategic partnership to advance IMU’s AI-powered High Definition (HD) Immunology platform for immune mapping in cancer and other diseases.
The collaboration combines Waters Biosciences’ flow cytometry and single-cell technologies with IMU’s AI analytics to enable large-scale, real-time immune profiling and biomarker discovery, supported by data presented at CYTO 2026.
Waters (NYSE: WAT) launched the Waters TA Instruments Coin Cell Differential Scanning Calorimeter (DSC) to advance battery safety testing. The system integrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway and battery failure.
Its whole-cell capsule design eliminates coin cell teardown, reducing sample preparation time by more than 90% while preserving sample integrity. With an industry-leading –80 °C to 600 °C temperature range and compatibility with MS, FTIR, and GC-MS, the Coin Cell DSC targets faster, multidimensional battery research. Orders are open, with shipments expected from August 2026.
Waters (NYSE:WAT) launched BioResolve Peptide and GTxResolve Lipid Phenyl-Hexyl+ and C18+ reversed-phase columns to improve characterization of GLP-1 peptides, insulin, and lipid nanoparticles (LNPs). The platform delivers up to 3x faster GLP-1 analysis and 2x faster LNP component analysis with increased resolving power and sensitivity.
According to Waters, the new columns offer up to 2x higher resolution, QC batch-tested GLP‑1 and LNP methods, improved impurity detection, and compatibility across U(H)PLC and HPLC systems. Global availability begins June 9, 2026, starting with the 1.6 µm Phenyl-Hexyl+ phase.